000177253 001__ 177253
000177253 005__ 20240229133735.0
000177253 0247_ $$2doi$$a10.1186/s13014-021-01938-8
000177253 0247_ $$2pmid$$apmid:34717680
000177253 037__ $$aDKFZ-2021-02387
000177253 041__ $$aEnglish
000177253 082__ $$a610
000177253 1001_ $$00000-0002-3630-0000$$aHöfel, Sebastian$$b0
000177253 245__ $$aProspective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy.
000177253 260__ $$aLondon$$bBioMed Central$$c2021
000177253 3367_ $$2DRIVER$$aarticle
000177253 3367_ $$2DataCite$$aOutput Types/Journal article
000177253 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635926714_26029
000177253 3367_ $$2BibTeX$$aARTICLE
000177253 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177253 3367_ $$00$$2EndNote$$aJournal Article
000177253 500__ $$a#LA:E055#
000177253 520__ $$aIn-vivo dosimetry (IVD) is a patient specific measure of quality control and safety during radiotherapy. With regard to current reporting thresholds for significant occurrences in radiotherapy defined by German regulatory authorities, the present study examines the clinical feasibility of superficial electron paramagnetic resonance (EPR) IVD of cumulative total doses applied to breast cancer patients treated with helical intensity-modulated radiotherapy (tomotherapy).In total, 10 female patients with left- or right-sided breast cancer were enrolled in this prospective IVD study. Each patient received a hypofractionated whole breast irradiation. A total median dose of 42.4 Gy in 16 fractions (5 fractions per week) was prescribed to the planning target volume. The treatments were completely delivered using helical tomotherapy and daily image guidance via megavoltage CT (MVCT). For each patient, three EPR dosimeters were prepared and placed at distinct locations on the patient's skin during the delivery of all fractions. Two dosimeters were placed next to the ipsilateral and contralateral mammilla and one dosimeter was placed ventrally to the thyroid (out-of-primary-beam). The total doses delivered to the dosimeters were readout after all fractions had been administered. The measured total dose values were compared to the planned dose values derived from the treatment planning system (TPS). Daily positional variations (displacement vectors) of the ipsilateral mammilla and of the respective dosimeter were analyzed with respect to the planned positions using the daily registered MVCT image.Averaged over all patients, the mean absolute dose differences between measured and planned total dose values (± standard deviation (SD)) were: 0.49 ± 0.85 Gy for the ipsilateral dosimeter, 0.17 ± 0.49 Gy for the contralateral dosimeter and -0.12 ± 0.30 Gy for the thyroid dosimeter. The mean lengths of the ipsilateral displacement vectors (± SD) averaged over all patients and fractions were: 10 ± 7 mm for the dosimeter and 8 ± 4 mm for the mammilla.Superficial EPR IVD is suitable as additional safeguard for dose delivery during helical tomotherapy of breast cancer. Despite positional uncertainties in clinical routine, the observed dose deviations at the ipsilateral breast were on average small compared to national reporting thresholds for total dose deviations (i.e. 10%/4 Gy). EPR IVD may allow for the detection of critical dose errors during whole breast irradiations.
000177253 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000177253 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177253 650_7 $$2Other$$aAlanine
000177253 650_7 $$2Other$$aBreast cancer
000177253 650_7 $$2Other$$aEPR dosimetry
000177253 650_7 $$2Other$$aHypofractionated
000177253 650_7 $$2Other$$aIMRT
000177253 650_7 $$2Other$$aIn vivo
000177253 650_7 $$2Other$$aLithium formate
000177253 650_7 $$2Other$$aRadiotherapy
000177253 650_7 $$2Other$$aTomotherapy
000177253 7001_ $$aGandalini, Matteo$$b1
000177253 7001_ $$aFix, Michael K$$b2
000177253 7001_ $$aDrescher, Malte$$b3
000177253 7001_ $$0P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aZwicker, Felix$$b4$$eLast author$$udkfz
000177253 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-021-01938-8$$gVol. 16, no. 1, p. 209$$n1$$p209$$tRadiation oncology$$v16$$x1748-717X$$y2021
000177253 909CO $$ooai:inrepo02.dkfz.de:177253$$pVDB
000177253 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177253 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000177253 9141_ $$y2021
000177253 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-08-28
000177253 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-28
000177253 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-28
000177253 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x0
000177253 980__ $$ajournal
000177253 980__ $$aVDB
000177253 980__ $$aI:(DE-He78)E055-20160331
000177253 980__ $$aUNRESTRICTED